Iovance biotherapeutics, inc. (IOVA)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenues

-

-

-

0

0

0

0

0

0

0

0

Costs and expenses
Operating expenses

-

-

-

-

-

-

-

6,476

19,302

643

15

Research and development expenses

166,023

99,828

71,615

26,941

15,470

3,849

2,154

1,656

1,755

171

0

General and administrative expenses

40,849

28,430

21,262

26,698

12,390

8,192

3,831

-

-

-

-

Cost of Lion transaction

-

-

-

-

-

-

16,656

0

-

-

-

Impairment of intangible asset

-

-

-

-

-

-

-

0

160

0

0

Total costs and expenses

206,872

128,258

92,877

53,639

27,860

12,041

22,641

8,132

21,218

815

15

Loss from operations

-206,872

-128,258

-92,877

-53,639

-27,860

-12,041

-22,641

-8,132

-21,218

-815

-15

Other income
Interest income, net

9,316

4,678

813

745

200

6

-445

-1,922

-

-

-

Interest (expense) income

-

-

-

-

-

-

-

-

151

0

0

Change in fair value of derivative liabilities

-

-

-

-

-

-

-

8,635

1,596

-229

0

Amortization of discount on convertible notes

-

-

-

-

-

-

-

497

5,000

0

0

Cost to induce exchange transaction

-

-

-

-

-

-

2,296

0

-

-

-

Financing costs

-

-

-

-

-

-

-

1,390

-

-

-

Private placement costs

-

-

-

-

-

-

-

-

920

563

0

Total other income (expense)

-

-

-

-

-

-

-2,741

4,824

-4,475

-792

0

Net Loss

-197,600

-123,580

-92,064

-52,894

-27,660

-12,035

-25,382

-3,307

-25,694

-1,607

-15

Deemed dividend related to beneficial conversion feature of convertible preferred stock

-

-

-

49,454

0

0

8,462

0

-

-

-

Net Loss Attributable to Common Stockholders

-

-

-

-102,348

-27,660

-12,035

-33,844

-3,307

-

-

-

Net Loss Per Common Share, Basic and Diluted

-1.59

-1.27

-1.41

-1.85

-0.62

-0.48

-3.47

-4.14

-0.34

-0.02

0.00

Weighted Average Common Shares Outstanding, Basic and Diluted

124

97

65

55

44

24

9,762

798

75,923

65,246

38,100